Cover Image
市場調查報告書

慢性阻塞性肺病 (COPD) :流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析

Chronic obstructive pulmonary disease: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365209
出版日期 內容資訊 英文 549 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性阻塞性肺病 (COPD) :流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析 Chronic obstructive pulmonary disease: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 549 Pages
簡介

本報告提供慢性阻塞性肺病 (COPD)的已上市及臨床實驗中 (開發平台上)的治療藥為焦點,提供多數的LABA/LAMA組合醫藥品及三倍組合醫藥品的登場,對金字塔性存在的Spiriva的影響,呼吸系統科醫生喜好的LABA/LAMA組合醫藥品,在治療的選擇中治療頻率發揮的作用,學名藥的可用性對主要上市藥的銷售額的影響,及COPD的生技藥品所扮演的角色等相關分析。

預測:慢性阻塞性肺病 (COPD)

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Advair (fluticasone/salmeterol)
  • Anoro Ellipta (umeclidinium/vilanterol)
  • Arcapta (indacaterol)
  • Breo (fluticasone furoate/vilanterol)
  • CHF 5993 (beclometasone/formoterol/glycopyrrolate)
  • Daliresp (roflumilast)
  • Duaklir Genuair (aclidinium/formoterol)
  • Dulera (mometasone/formoterol)
  • FF/UMEC/VI (fluticasone/umeclidinium/vilanterol)
  • Incruse (umeclidinium)
  • Nucala (mepolizumab)
  • PT003 (formoterol/glycopyrrolate)
  • PT010 (budesonide/glycopyrronium/Formoterol)
  • Seebri Breezhaler (glycopyrrolate)
  • Spiriva (tiotropium)
  • Stiolto Respimat (olodaterol/tiotropium)
  • Striverdi Respimat (olodaterol)
  • Symbicort (budesonide/formoterol)
  • Tudorza Pressair (aclidinium)
  • Ultibro (indacaterol/glycopyrronium bromide)
  • 1次調查手法

治療:慢性阻塞性肺病 (COPD)

  • 摘要整理
  • 1次調查手法
  • 疾病定義、診斷
  • 患者區分
  • 各國治療系統
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求
  • 開發平台藥物、未來的治療

的COPD流行病學:美國、日本、EU5個國家

  • 摘要整理
  • 疾病的背景
  • 來源、手法
  • 預測
  • 流行病學者的見解
  • 優勢和弱點
  • 參考文獻

流行病學:巴西的COPD

  • 摘要整理
  • 疾病的背景
  • 來源、手法
  • 預測
  • 流行病學者的見解
  • 優勢和弱點
  • 參考文獻

上市藥:慢性阻塞性肺病 (COPD)

  • 摘要整理
  • 產品概要
  • 其他上市藥
  • 附錄
  • 產品簡介: Advair
  • 產品簡介: Anoro
  • 產品簡介: Arcapta Neohaler
  • 產品簡介: Breo
  • 產品簡介: Daliresp
  • 產品簡介: Duaklir Genuair
  • 產品簡介: Incruse
  • 產品簡介: Seebri Breezhaler
  • 產品簡介: Spiriva
  • 產品簡介: Stiolto Respimat
  • 產品簡介: Striverdi Respimat
  • 產品簡介: Symbicort
  • 產品簡介: Tudorza Pressair
  • 產品簡介: Ultibro

開發平台:慢性阻塞性肺病 (COPD)

  • 摘要整理
  • 臨床實驗平台概要
  • 最近中止的藥物
  • 附錄
  • 產品簡介 (後期階段) : CHF 5993
  • 產品簡介 (late stage): FF/UMEC/VI
  • 產品簡介 (late stage): Nucala
  • 產品簡介 (late stage): PT003
  • 產品簡介 (late stage): PT010
  • 產品簡介 (late stage): benralizumab

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5952

While the chronic obstructive pulmonary disease (COPD) market will see downward pressure from the arrival of generic versions of key marketed brands, new products will drive positive growth during 2015-24.

This report addresses the following questions:

  • How will the emergence of numerous long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combinations and triple combinations impact the gold standard Spiriva?
  • Which are the preferred LABA/LAMA combinations among pulmonologists?
  • How will triple combination therapies fit into the COPD treatment algorithm?
  • What role will administration frequency play in choice of therapy?
  • How will the availability of generics affect sales of key marketed drugs?
  • What role will biologics play in COPD?

TABLE OF CONTENTS

FORECAST: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Advair (fluticasone/salmeterol)
  • 5. Anoro Ellipta (umeclidinium/vilanterol)
  • 6. Arcapta (indacaterol)
  • 7. Breo (fluticasone furoate/vilanterol)
  • 8. CHF 5993 (beclometasone/formoterol/glycopyrrolate)
  • 9. Daliresp (roflumilast)
  • 10. Duaklir Genuair (aclidinium/formoterol)
  • 11. Dulera (mometasone/formoterol)
  • 12. FF/UMEC/VI (fluticasone/umeclidinium/vilanterol)
  • 13. Incruse (umeclidinium)
  • 14. Nucala (mepolizumab)
  • 15. PT003 (formoterol/glycopyrrolate)
  • 16. PT010 (budesonide/glycopyrronium/Formoterol)
  • 17. Seebri Breezhaler (glycopyrrolate)
  • 18. Spiriva (tiotropium)
  • 19. Stiolto Respimat (olodaterol/tiotropium)
  • 20. Striverdi Respimat (olodaterol)
  • 21. Symbicort (budesonide/formoterol)
  • 22. Tudorza Pressair (aclidinium)
  • 23. Ultibro (indacaterol/glycopyrronium bromide)
  • 24. Primary Research Methodology

TREATMENT: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  • 25. Executive Summary
  • 26. Primary Research Methodology
  • 27. Disease Definition and Diagnosis
  • 28. Patient Segmentation
  • 29. Country Treatment Trees
  • 30. Current Treatment Options
  • 31. Prescribing Trends
  • 32. Unmet Needs in Chronic Obstructive Pulmonary Disease
  • 33. Pipeline Drugs and Future Treatment

EPIDEMIOLOGY: COPD IN THE US, JAPAN, AND 5EU

  • 34. Executive Summary
  • 35. Disease Background
  • 36. Sources and Methodology
  • 37. Forecast
  • 38. Epidemiologist Insight
  • 39. Strengths and Limitations
  • 40. Bibliography

EPIDEMIOLOGY: COPD IN BRAZIL

  • 41. Executive Summary
  • 42. Disease Background
  • 43. Sources and Methodology
  • 44. Forecast
  • 45. Epidemiologist Insight
  • 46. Strengths and Limitations
  • 47. Bibliography

MARKETED DRUGS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  • 48. Executive Summary
  • 49. Product Overview
  • 50. Other Marketed Drugs for COPD
  • 50. Appendix
  • 51. Product profile: Advair
  • 52. Product profile: Anoro
  • 53. Product profile: Arcapta Neohaler
  • 54. Product profile: Breo
  • 55. Product profile: Daliresp
  • 56. Product profile: Duaklir Genuair
  • 57. Product profile: Incruse
  • 58. Product profile: Seebri Breezhaler
  • 59. Product profile: Spiriva
  • 60. Product profile: Stiolto Respimat
  • 61. Product profile: Striverdi Respimat
  • 62. Product profile: Symbicort
  • 63. Product profile: Tudorza Pressair
  • 64. Product profile: Ultibro

PIPELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  • 65. Executive Summary
  • 66. Clinical Pipeline Overview
  • 67. Recently Discontinued Drugs
  • 68. Appendix
  • 69. Product profile (late stage): CHF 5993
  • 70. Product profile (late stage): FF/UMEC/VI
  • 71. Product profile (late stage): Nucala
  • 72. Product profile (late stage): PT003
  • 73. Product profile (late stage): PT010
  • 74. Product profile (late stage): benralizumab
Back to Top